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Aerobic Exercise and 
Pharmacological Treatments 
Counteract Cachexia by Modulating 
Autophagy in Colon Cancer
Eva Pigna1, Emanuele Berardi1,2, Paola Aulino1, Emanuele Rizzuto3, Sandra Zampieri4,5, 
Ugo Carraro6, Helmut Kern5, Stefano Merigliano7, Mario Gruppo7, Mathias Mericskay8, 
Zhenlin Li8, Marco Rocchi9, Rosario Barone10, Filippo Macaluso10, Valentina Di Felice10, 
Sergio Adamo1, Dario Coletti1,8 & Viviana Moresi1
Recent studies have correlated physical activity with a better prognosis in cachectic patients, although 
the underlying mechanisms are not yet understood. In order to identify the pathways involved in the 
physical activity-mediated rescue of skeletal muscle mass and function, we investigated the effects of 
voluntary exercise on cachexia in colon carcinoma (C26)-bearing mice. Voluntary exercise prevented 
loss of muscle mass and function, ultimately increasing survival of C26-bearing mice. We found that the 
autophagic flux is overloaded in skeletal muscle of both colon carcinoma murine models and patients, 
but not in running C26-bearing mice, thus suggesting that exercise may release the autophagic flux and 
ultimately rescue muscle homeostasis. Treatment of C26-bearing mice with either AICAR or rapamycin, 
two drugs that trigger the autophagic flux, also rescued muscle mass and prevented atrogene 
induction. Similar effects were reproduced on myotubes in vitro, which displayed atrophy following 
exposure to C26-conditioned medium, a phenomenon that was rescued by AICAR or rapamycin 
treatment and relies on autophagosome-lysosome fusion (inhibited by chloroquine). Since AICAR, 
rapamycin and exercise equally affect the autophagic system and counteract cachexia, we believe 
autophagy-triggering drugs may be exploited to treat cachexia in conditions in which exercise cannot 
be prescribed.
Cancer is a major, worldwide health problem that is responsible for one in four deaths1,2. Numerous studies have 
investigated the association between physical activity and a lower risk of developing cancer. A striking find-
ing that recently emerged from both epidemiological studies and clinical trials is that the improved prognosis 
observed in physically active cancer patients is due to the exercise performed after cancer diagnosis as opposed 
to exercise habits before the disease3,4. Depending on the tumor type, 9 to 18 metabolic equivalent task (MET) 
hours per week of physical activity yielded significant benefits when compared with a sedentary lifestyle (9 MET 
hours/week are equivalent to 5 weekly 30-minute sessions of brisk walking)5. While physical activity following 
diagnosis lowers the risk of both cancer-specific and overall mortality, physical activity spontaneously declines 
in cancer patients and such patients do not exercise enough even after tumor resection6. Although exercise 
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increases survival in cancer patients and improves their quality of life7, prescribing exercise to these patients is 
not a straightforward task. It is, thus, of paramount importance to identify potential pharmacological treatments 
that may be able to mimic the effects of exercise in pathological conditions. While clinical studies have shown that 
exercise has a highly beneficial effect on cancer patients, it should be borne in mind that such studies are obser-
vational by nature, and that the cause and effect cannot consequently be assumed; in addition, they fail to provide 
insights into possible mechanisms that could be exploited for pharmacological treatments.
A major cause of patient mortality, morbidity and low quality of life, including exercise intolerance, is 
cancer-associated cachexia. Cachexia is defined as “a complex metabolic syndrome associated with underlying 
illness and characterized by loss of muscle with or without loss of fat mass. Anorexia, inflammation, insulin 
resistance and increased muscle protein breakdown are frequently associated with wasting disease”8,9. Cachexia 
is not a condition that is exclusive to cancer, it being shared by several chronic diseases and severe acute injuries. 
Cachexia bears some similarities to sarcopenia and other forms of muscle atrophy, even though it remains distinct 
at both the morphological and molecular levels10. Cancer cachexia is probably the most severe form of muscle 
atrophy and is associated with increased morbidity and mortality10. In the case of treated cancers, chemotherapy 
per se induces muscle wasting regardless of tumor progression, thereby exacerbating cachexia and worsening the 
patient’s quality of life; cachexia, in turn, interferes with the efficacy and practicability of chemotherapies. We and 
others have demonstrated that the expression of both muscle fiber and satellite cell genes are affected in cachexia, 
clearly indicating that cancer-induced muscle wasting does not result from a general loss of muscle proteins but 
derives from the selective dysregulation of key muscle gene products11. Several therapeutic strategies have been 
adopted in an attempt to counteract cancer cachexia, to improve the quality of life and to increase life expectancy 
of patients12. However, therapeutic approaches based on a single target, such as the use of recombinant antibodies 
against tumor necrosis factor, have failed so far, the most likely cause being that cancer cachexia is triggered by 
multiple factors.
Exercise training has long been proposed to counteract cachexia. Indeed, stimulation of muscle contraction 
has been shown to reduce muscle wasting in tumor-bearing animals13. The molecular bases of skeletal muscle 
adaptation to exercise have been extensively reviewed14. In tumor-bearing mice, muscular damage may arise 
from tumor-induced dysregulation of dystrophin expression15, which increases muscle fragility. Since exposing 
tumor-bearing mice, and possibly even humans, to exercise protocols might be deleterious, pharmacological 
alternatives to physical activity are needed.
In this regard, pharmacological treatments are being proposed to mimic the beneficial effects of exercise in an 
attempt to replace or supplement exercise-training programs. These compounds, which are referred to as “exer-
cise mimetics”16,17, may represent a very promising tool for the treatment of severe muscular and non-muscular 
pathologies16,18. Indeed, they induce muscle responses that are similar to those mediated by endurance exer-
cise17. In particular, the AMP analog 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) is an 
AMP-activated protein kinase (AMPK) activator that increases endurance in sedentary mice by reprogramming 
muscle metabolism17. AICAR mimics the typical increase in the AMP/ATP ratio that occurs following exercise, 
ultimately activating the AMPK; hence, the expression “exercise mimetics”16. Indeed, in response to exercise 
or exercise mimetics, AMPK integrates multiple transcriptional programs by interacting with transcriptional 
regulators of the metabolism, such as peroxisome proliferator-activated receptor gamma coactivator 1a (PGC1a) 
and peroxisome proliferator-activated receptor (PPAR), and by inhibiting the mammalian target of rapamycin 
(mTOR) signaling18. Moreover, by opposing mTOR signaling19 and by activating FoxO3a20, AMPK promotes 
skeletal muscle autophagy. The inhibition of mTOR mediates many of the effects of rapamycin, another drug 
used as an immunosuppressant and disruptor of signaling controlling muscle homeostasis21. Rapamycin also 
stimulates autophagy22.
Autophagy takes place at basal levels in all eukaryotic cells, turning over long-lived macromolecules and large 
supramolecular structures. The excessive activation of autophagy aggravates muscle wasting23,24. By contrast, 
inhibition of lysosome-dependent degradation causes myopathies such as Pompe and Danon diseases, and auto-
phagy inhibition is believed to play a role in many myopathies characterized by inclusion bodies or abnormal 
mitochondria, as well as in dystrophies25,26. Accordingly, autophagy is required to maintain muscle mass27.
Here we present data showing that cancer triggers the induction of the autophagic markers LC3b and p62/
SQSTM 1 in skeletal muscle in both mice and carcinoma patients. This scenario is deleterious to muscle as well 
as to other tissues28. Aerobic exercise and pharmacological treatments that promote autophagy restore muscle 
homeostasis and modulate autophagy in cancer cachexia. These observations shed light on a possible mechanism 
underlying the beneficial effects observed in cancer patients who perform a moderate amount of physical activ-
ity, and highlight the role of autophagy-triggering drugs as a potential therapeutic approach to treating cancer 
patients.
Results
Voluntary wheel running counteracts cancer cachexia. We allowed healthy and C26-bearing mice to 
perform voluntary wheel running (WR) by equipping their cages with a wheel, to avoid muscle damage resulting 
from imposed, forced exercise protocols such as a treadmill. None of the tumor-bearing mice interrupted the 
running activity as the disease progressed, which suggests that they were not subjected to major discomfort. 
Nonetheless, we measured muscle damage in both control and C26-bearing mice, which underwent or did not 
undergo two different routines of voluntary physical activity (5 and 19 days of WR), to determine whether WR 
exacerbates muscle damage in cachexia. By quantifying Evans’ Blue dye (EBD) uptake by two different mus-
cles, which is considered a marker of cell impairment, we confirmed that the C26 tumor induces muscle fiber 
damage, and we found that WR per se did not damage or interact with tumor-induced muscle fiber damage 
(Supplementary Fig. S1). Running activity was monitored daily by measuring several parameters, including the 
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running distance, in both control and C26-bearing mice (Table 1). The results show that C26-bearing mice were 
still capable of running, though to a lesser extent than control mice but at a similar intensity.
To quantify the effects of WR on parameters commonly used as diagnostic criteria for cachexia8, we compared 
several groups of animals: control (i.e. healthy) mice in the absence and presence of WR, and C26 tumor-bearing 
mice in the absence and presence of WR and of pharmacological treatments used as replacements for WR. In 
terms of final weight (i.e. carcass weight, which is the body weight minus tumor weight), we found no effect of 
WR on healthy mouse body weight; instead, all the treatments (i.e. WR and drug administrations) affected body 
weight by interfering with the C26-induced body weight loss (Table 2).
Since WR prevented the severe body weight loss that characterizes cachexia and since skeletal muscle mass 
accounts for about 50% of the body mass, a rescue of muscle homeostasis was a predicted outcome. Thus, we 
measured the effects of exercise on a specific representative muscle, i.e. the tibialis anterior (TA), and found that 
WR increased TA mass in C26-bearing mice (Fig. 1a). Histological and morphometric analyses of the mus-
cle fiber cross-sectional area (CSA), performed by using immunostaining for laminin to visualize the myofiber 
perimeter, revealed a significantly bigger CSA in exercised C26-bearing mice than in sedentary C26-bearing mice 
(Fig. 1b,c).
Along with muscle mass, WR improved muscle function in C26-bearing mice: the extensor digitorum longus 
(EDL) muscle, a muscle that we previously found to be affected in cancer cachexia29, exhibited a shorter fatigue 
time (defined as the time required to halve the value of the muscle maximum strength) in C26-bearing con-
trol mice than in non-C26-bearing control mice, while no differences were detected in WR C26-bearing mice 
(Fig. 1d). A negative interaction between the C26-induced decrease in fatigue time and WR was found, which 
thus indicates that WR rescues muscle function in C26-bearing mice.
Given the many positive effects exerted by WR on skeletal muscle homeostasis and function, we sought to 
verify whether WR might extend the life span of C26-bearing mice. Since the presence of a wheel in the cage may 
represent a form of environmental enrichment30, we also included, as an additional control, treatments designed 
to test whether environmental enrichment had significant effects per se on mouse survival. Thus, we combined 
the use of regular or environmentally-enriched (EE) cages (Supplementary Fig. S2a) with the absence or presence 
of the wheel to evaluate the survival of C26-bearing mice. WR significantly increased survival in C26-bearing 
mice whereas EE cages alone did not (Supplementary Fig. S2b). We also observed that the effects of WR were 
maintained in EE cages (not shown in the figure), thus suggesting that WR and environmental enrichment do 
not affect each other.
WR activity increased the life span of C26-bearing mice by about 44%, thus indicating that voluntary physical 
activity had a marked beneficial effect on animal models of cancer cachexia, as previously reported in clinical 
Total distance 
(Km)
Partial distance* 
(Km)
Distance/day* 
(Km/d) Time* (h:min)
Speed* 
(Km/h)
CTR WR 145 ± 11 51 ± 4 10.4 ± 0.3 20:59 ± 4:30 2.1 ± 0.1
C26 WR 105 ± 20 31 ± 10 6.3 ± 1.9 13:29 ± 6:20 1.9 ± 0.1
Table 1.  Wheel-running activity. Control mice (CTR) and C26-bearing mice (C26) were kept in wheel-
equipped cages and performed 19 days of voluntary wheel-running (WR) activity, which was individually 
recorded. * parameter values are based on the last five days, which correspond to a plateau phase of exercise 
activity and to overt cachexia in C26-bearing mice. The means ± SEM are shown. Tumor-bearing mice perform 
voluntary wheel running even in advanced stages of the disease.
Initial body weight (g) Final body weight (g)
CTR 18.3 ± 0.4 19.5 ± 0.5* * 
CTR WR 18.7 ± 0.6 19.8 ± 0.4* 
C26 18.7 ± 0.4 15.6 ± 0.4* * 
C26 WR 18.4 ± 0.34 19.7 ± 0.4##
C26 AICAR 18.9 ± 0.6 18.5 ± 0.9#
C26 RAPA 19.4 ± 0.8 19.4 ± 0.6###
Table 2.  Mouse body weight according to treatments. Mice were divided into the following six groups: 
control mice (CTR); wheel-running mice (WR); tumor-bearing mice (C26); tumor-bearing, running mice  
(C26 WR); tumor-bearing, AICAR-treated mice (C26 AICAR); tumor-bearing, rapamycin-treated mice (C26 
RAPA). All the treatments lasted 19 days, as explained in detail in the Methods, and the initial and final body 
weight were measured (the final weight of C26-bearing mice was equal to the carcass weight, i.e. total body 
weight minus tumor weight). Two-way ANOVA for repeated measures revealed no effect of WR on the body 
weight of healthy mice (control) but a significant effect of the presence of the tumor on the body weight of C26-
bearing mice. In addition, ANOVA showed that the treatments had a significant effect in rescuing body weight. 
Multiple comparisons by Tukey’s HSD tests were used as post-hoc tests: * * p < 0.0005 vs initial; * p = 0.001 
vs initial; ##p < 0.0005 vs C26 final; #p = 0.001 vs C26 final. C26 WR is NS vs C26 AICAR or C26 RAPA. 
The means ± SEM are shown; 9 < n < 34 for each group. The results show that each treatment significantly 
counteracts the C26-induced body weight loss.
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studies. In order to assess any correlation between individual variations in the amount of exercise with output in 
terms of survival, we measured the daily distance covered by WR and the lifespan of the corresponding mouse in 
a subset of randomly chosen animals. This approach revealed a striking, linear correlation between km/day run 
on the wheel and survival time: each km/day of running activity was found to correspond to four additional days 
of survival in C26-bearing mice (Fig. 1f).
In keeping with all the aforementioned findings, WR was also found to be associated with a significant increase 
in food intake in WR C26-bearing mice compared with control C26-bearing mice (Supplementary Fig. S3). 
Moreover, the fact that food intake in C26-bearing mice did not change over time indicates that this tumor does 
not induce anorexia in mice as it progresses.
Voluntary wheel running counteracts alterations in catabolic pathways in colon carcinoma 
(C26)-bearing mice. Cachexia is characterized by an up-regulation of the muscle specific E3-ubiquitin 
ligases, atrogin 1 and MuRF131. When we quantified the effects of both C26 and WR on these markers in skeletal 
muscle, we found that both ubiquitin ligases were significantly up-regulated in muscle from C26-bearing mice 
when compared with control healthy mice, and that voluntary wheel running prevented the induction of these 
genes and consequently restored expression levels to those of controls (Fig. 2a).
Figure 1. Voluntary wheel running counteracts cancer cachexia and prolongs survival of tumor-bearing 
mice. (a) TA muscle weight of C26-bearing mice in the absence (—) or presence (WR) of voluntary wheel 
running for 19 days. WR rescues muscle mass of C26-bearing mice. Data are shown as mean ± SEM; 6 < n < 9 
for each group, * p < 0.05 by Student’s t-test. (b) Representative immunostaining for laminin on TA muscle 
of C26-bearing mice in the absence (—) or presence (WR) of wheel running for 19 days, showing that WR 
increases fiber size and improves basement membrane morphology in C26-bearing mice. Scale bar = 100 
microns. (c) Median ± SEM of glycolytic TA myofiber cross-sectional area of C26-bearing mice in the absence 
(—) or presence (WR) of wheel running for 19 days. WR rescues fiber size of C26-bearing mice. n = 5 for 
each group, * p < 0.05 by Student’s t-test. (d) Fatigue time of EDL muscle of control or C26-bearing mice in 
the absence (—) or presence (WR) of wheel running for 19 days. Data are shown as mean ± SEM. Two-way 
ANOVA (F = 5.77; df 1; p = 0.025) shows an interaction between the negative effect of C26 tumor and wheel 
running, which restores fatigue time to control levels; data are shown as mean ± SEM; 6 < n < 9 for each group, 
* p < 0.05 by Tukey’s HSD test. (e) Survival curves derived from Cox model for statistical analysis of C26-
bearing mice in the absence (C26, circles) or presence (C26 WR, triangles) of wheel running. Wheel running 
significantly (p < 0.041) increased survival of C26-bearing mice. n = 9 for each group. (f) Linear correlation 
between running distance (Km per day) and life span (days of survival) in C26-bearing mice. From the curve 
equation, one can infer that each km/day of wheel running corresponds to an increase of approximately 4 days 
in life span.
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Figure 2. Wheel running counteracts tumor-induced atrogene expression and restores the autophagic 
marker levels, which are altered in both murine and human skeletal muscle in cancer cachexia.  
(a) Expression of Atrogin 1 and MuRF1 genes by real-time RT-PCR, in mice in the absence (—) or presence 
(WR) of wheel running, 19 days after transplantation in C26-bearing mice and in control mice (CTR). Values 
were normalized to Gapdh expression. Data are presented as mean ± SEM. Kruskal-Wallis test revealed a 
global significant difference between the three groups, followed by post-hoc test * p < 0.05. (b) Representative 
immunostaining for p62 on TA muscle of C26-bearing mice in the absence (—) or presence (WR) of wheel 
running for 19 days, showing an increase of p62 induction in C26-bearing mice. Scale bar = 20 microns.  
(c) Western blot analysis of LC3bI, LC3bII and p62 expression in control mice (CTR), or mice in the absence 
(—) or presence (WR) of wheel running, 19 days after C26 transplantation. Gapdh was used as a loading 
control. Densitometric analyses of Western blot showing LC3bII/LC3bI ratio (d) and p62/Gapdh (e) ratio in 
mice in the absence (—) or presence (WR) of wheel running, 19 days after C26 transplantation, compared 
with control mice (CTR). Data are presented as mean ± SEM. F = 4.63; df 2; p < 0.05 and F = 14.18; df 2; 
p < 0.02 by ANOVA; *p < 0.005 and ** p < 0.005 by Tukey’s HSD test. (f) Expression of LC3b and p62 by 
Western blot analyses in skeletal muscle biopsies from colon carcinoma patients and healthy (CTR) subjects. 
Gapdh was used as a loading control. The lanes were run on the same type of gel but were non-contiguous, 
as indicated by the thin black lines. Densitometric analyses of Western blot showing significantly higher 
expression of LC3bII/LC3BI ratio (g) and p62/Gapdh ratio (h) in skeletal muscle biopsies from colon 
carcinoma patients (CARC), compared with healthy subjects (CTR). Data are presented as mean ± SEM.  
* p < 0.05 by Student’s t-test.
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It has recently been suggested that autophagy contributes to the pathogenesis of skeletal muscle wasting in 
cancer cachexia32. Using electron microscopy, we detected autophagosome-like structures in skeletal muscle fib-
ers of C26-bearing mice (Supplemental Fig. S4), which is consistent with similar morphological findings observed 
at the ultrastructural level in other muscle pathologies33.
As aerobic exercise is known to trigger autophagy in skeletal muscle34, we decided to evaluate autophagy 
in our experimental conditions by immunostaining for p62 and Western blot analyses for LC3b and p62, as 
markers of autophagic induction. Immunofluorescence analyses on TA muscles detected accumulation of p62 
in C26-bearing mice, if compared with control or WR C26-bearing mice (Fig. 2b). The activation of autophagy 
drives the processing of LC3bI into its lipidated, autophagosome-bound form LC3bII, with a high LC3bII/LC3bI 
ratio being considered to indicate an increased number of autophagosomes. We observed an increase in the lev-
els of the LC3bII/LC3bI and p62/Gapdh ratio in C26-bearing mice (Fig. 2c–e), compared with control healthy 
mice, which is in agreement with findings by Penna et al.32. Interestingly, WR significantly reduced the LC3bII/
LC3bI and p62/Gapdh ratio in C26-bearing mice (Fig. 2d,e). These findings confirm that autophagy is activated 
in sedentary C26-bearing mice; nevertheless, the sustained expression of p62 suggests that the autophagic flux 
may, despite not being blocked completely, proceed at a slower rate. Voluntary WR exercise appears to restore 
basal levels of autophagy, which is beneficial to muscle homeostasis insofar as it is associated with the recovery of 
muscle mass and function.
To validate previous observations yielded by the C26-bearing mouse model, we compared the levels of expres-
sion of the aforementioned autophagy-related proteins with data obtained from skeletal muscle biopsies of colon 
carcinoma patients. Remarkably, accumulation of the lipidated form of LC3b, a high LC3bII/LCb3I ratio and sig-
nificantly higher p62 levels were detected in skeletal muscle of colon carcinoma patients compared with healthy 
subjects (Fig. 2f–h). The pathological classification of tumors, gender, age, BMI were recorded for this cohort of 
patients, together with the levels of the following parameters: total proteins, albumin and transthyretin, creatine 
kinase, C-reactive protein and leukocytes (Supplementary Tables 1 and 2). Other events and chemotherapy treat-
ments were also taken into account. No significant correlation between p62 levels and any of these parameters 
was found. The lack of significant differences between patients suggests that it is possible to pool patients for the 
p62 analysis.
By showing that both tumor-bearing mice and patients display altered autophagic markers, our results indicate 
that such alterations in the autophagic system may play a role in the development of cachexia. This prompted us 
to further investigate the efficacy of pharmacological treatments designed to trigger autophagy in cancer-induced 
cachexia.
Drugs promoting autophagy counteract body weight loss in cancer cachexia. As described 
above, AICAR is a pharmacological activator of AMPK17 that has been shown to recapitulate the molecu-
lar response of skeletal muscle to aerobic exercise and to promote autophagy14,35. We therefore treated, on a 
daily basis, C26-bearing mice with AICAR, or a vehicle for controls, by means of intraperitoneal injections. We 
confirmed the activation of AMPK and its downstream target ACC in skeletal muscles of AICAR-treated mice 
by Western blot analyses (Fig. 3a). Rapamycin, a specific inhibitor of mTOR, is another drug known to trigger 
autophagy in many cell types, including skeletal muscle36. In parallel experiments, we treated, on a daily basis, 
C26-bearing mice with rapamycin, or a vehicle for controls, by means of intraperitoneal injections, and con-
firmed the inhibition of mTOR in skeletal muscles of rapamycin-treated mice, by Western blot analyses (Fig. 3b). 
Treatment with AICAR prevented weight loss in C26-bearing mice, compared with vehicle-treated C26-bearing 
mice (Table 2). Accordingly, AICAR blocked skeletal muscle wasting in C26-bearing mice by restoring both 
muscle mass and myofiber size (Fig. 3c–e). Similarly, rapamycin treatment significantly affected cancer cachexia 
in C26-bearing mice by preventing a drop in body weight (Table 2), which in turn resulted in heavier and larger 
TA muscles than in vehicle-treated mice (Fig. 3c–e). These drugs were found to exert a significant effect on both 
the TA weight and muscle fiber CSA, thereby showing that pharmacological treatments are highly effective in 
counteracting muscle wasting in C26-bearing mice. Interestingly, no difference was detected between AICAR and 
rapamycin treatment in terms of body weight rescue in tumor-bearing mice (Table 2).
AICAR and rapamycin counteract muscle atrophy and affect autophagy. We compared the tran-
scriptional response to cancer cachexia in C26-bearing mice treated with either AICAR or rapamycin with that 
in vehicle-treated mice 19 days after tumor transplantation. Strikingly, both AICAR and rapamycin treatment 
significantly reduced atrogin 1 and MuRF1 expression levels, which were instead up-regulated in vehicle-treated 
C26-bearing mice (Fig. 4a). Similarly to voluntary wheel running, we found that both AICAR and rapamycin 
treatments modulated autophagy in C26-bearing mice by significantly reducing C26-mediated p62 accumulation, 
as revealed by immunofluorescence analyses on TA muscles (Fig. 4b). Moreover, quantification of LC3bII/LC3bI 
and p62/Gapdh protein levels by Western blot analyses confirmed the effects of both AICAR and rapamycin 
treatments on these autophagic markers (Fig. 4c–e).
AICAR and rapamycin affect skeletal muscle cells in vitro. Since both AICAR and rapamycin treat-
ments were administered systemically, to prove that they directly affect skeletal muscle cells, we reproduced 
our experimental model in vitro by treating C2C12 myotubes with conditioned media derived from C26 cells. 
Forty-eight hours of treatment with C26-conditioned media induced approximately 30% of myotube atrophy in 
vitro, as quantified by measuring myotube diameter, whereas both AICAR and rapamycin treatments counter-
acted C26-induced muscle atrophy (Fig. 5). The effects of these treatments in vitro suggest that autophagy plays 
a role in controlling myotube size; to prove that autophagy is involved in the control of the myotube mass, we 
interfered with the autophagic flux by treating cells with chloroquine, an agent that prevents the fusion between 
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autophagosomes and lysosomes37. A six-hour treatment with 50 microM chloroquine induced an accumulation 
of LC3b and p62 in myotubes (Supplementary Fig. S5), which is indicative of a block in the autophagic flux, and 
worsened myotube atrophy in all the conditions analyzed (Fig. 5).
Discussion
Cachexia most commonly presents in lung- or gastrointestinal tract-cancer patients38, who can lose as much as 
30% of their initial body weight. Since loss of strength and muscle mass are, together with involuntary loss of body 
weight39, the main features associated with cachexia, physical activity has proved to be a good therapeutic strategy 
to fight cachexia, thanks to its effects on both strength and muscle mass40. The molecular mechanisms underlying 
the physical activity-mediated rescue of cachexia are poorly understood. We show that all the major diagnos-
tic features of C26-induced cachexia, such as loss of body weight, skeletal muscle mass and fiber size, can be 
counteracted by voluntary wheel running in mice. Voluntary running also improves skeletal muscle function in 
C26-bearing mice by raising the fatigue threshold, a relevant finding if we consider that fatigue is one of the most 
frequently reported complaints of cachectic patients41. It is noteworthy that C26-bearing mice did not develop 
anorexia and, thus, represent a pure cachexia model42. Conventional nutritional support cannot fully reverse 
cachexia, though a limited beneficial effect of appetite stimulants has been observed in mouse models43. We 
observed a significant increase in appetite in C26-bearing running mice associated with an improvement in mus-
cle homeostasis, which suggests that exercise might have contributed to the improvement in muscle homeostasis 
by providing the aminoacids required for protein synthesis. Resistance exercise has traditionally been proposed 
to fight cachexia and other forms of muscle atrophy because it is a type of exercise that increases muscle protein 
content balance, mass, strength and resistance to fatigue. Here, we show that wheel running, which shares the fea-
tures of endurance training44, effectively counteracts muscle wasting; as opposed to activating pro-hypertrophic 
signaling pathways14, this type of exercise counteracts pro-atrophic NF-κ B-dependent signaling45. We observed 
a significant increase in life span in wheel running C26-bearing mice. Strikingly, life span directly correlates 
with the amount of voluntary running in C26-bearing mice. Exercise prolongs survival in both tumor-bearing 
mice and humans. However, since cancer patients, particularly the elderly, are often unable to perform voluntary 
exercise, any therapy based on voluntary running or other physical aerobic activities has certain limitations for 
cancer patients with progressive muscular atrophy. It is hence important i) to experimentally test alternative 
Figure 3. AICAR or rapamycin treatment counteracts muscle wasting in cancer cachexia. (a) Western 
blot showing total and phosphorylated AMPK levels, as well as ACC activation (p-ACC) in AICAR-treated 
mice, and (b) total and phosphorylated mTOR levels in rapamycin-treated mice (RAPA), compared with 
vehicle-treated mice (—) as well as untreated mice (CTR). Treatments consisted in daily IP injection of vehicle 
or [250 mg/Kg] AICAR (AICAR) or [2 mg/Kg] rapamycin (RAPA) for 19 days. (c) TA muscle weight of C26-
bearing mice in the absence (—) or presence of treatment as indicated. ANOVA (F = 9.47; df 2; p < 0.0005) 
revealed a significant effect of the treatments on TA weight. (d) Representative immunostaining for laminin 
on TA muscle of C26-bearing mice in the presence of the treatments indicated, showing increased fiber size in 
treated animals. Scale bar = 100 microns. (e) Median ± SEM of TA myofiber cross-sectional area of C26-bearing 
mice in the presence of the treatments indicated. ANOVA (F = 6.86; df 2; p < 0.008) revealed a significant effect 
of treatments on muscle fiber CSA (F, see results). Data are shown as mean ± SEM; 12 < n < 26 for each group,  
* p < 0.05 by Tukey’s HSD test.
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interventions, such as functional neuromodulation (i.e. electrical stimulation training of muscles) and ii) to iden-
tify the molecular pathways involved in voluntary running-mediated muscle rescue in cachexia. The latter is 
not merely due to an exercise-mediated shift toward a more oxidative fiber phenotype, as is shown by the fact 
that 19 days of wheel running did not significantly increase oxidative fibers44, which are considered to be more 
resistant to cancer cachexia46. Molecular analyses showed that wheel running reduces tumor-mediated atrogin 
1 and MuRF1 gene expression, thus demonstrating that aerobic physical activity counteracts muscle atrophy by 
targeting the catabolic pathways of protein degradation. Pioneering analyses of the effect of a bout of wheel run-
ning (more than 5 km during the first night) demonstrated that muscle damage/regeneration/repair are accompa-
nied by structural and molecular events associated with muscle apoptosis47,48. Apoptosis and inflammation share 
Figure 4. AICAR or rapamycin treatment counteracts the induction of atrogene expression and modulates 
autophagic markers in cancer cachexia. (a) Expression of Atrogin 1 and MuRF1 genes as shown by real-time 
RT-PCR, in mice that received daily IP treatment with vehicle (—), AICAR (AICAR) or rapamycin (RAPA), 
for 19 days after C26 implant, compared with control mice (CTR). Values were normalized to Gapdh. ANOVA 
(F = 10.08; df 3; p < 0.01;F = 7.90; df 3; p < 0.01; for Atrogin 1 and MuRF1, respectively) showed a significant 
effect of the treatments on ubiquitine-ligase relative expression. (b) Representative immunostaining for p62 on 
TA muscle of C26-bearing mice in the absence (—) or presence of the treatments indicated, showing an increase 
in p62 induction in C26-bearing mice. Scale bar = 20 microns. (c) Western blot analysis of LC3bI, LC3bII, p62 
and Gapdh expression in the presence of the treatments indicated. The lanes separated by the thin black lines 
were run at the same time on parallel gels and were, therefore, non-contiguous. (d) Densitometric analyses 
of Western blot showing LC3bII/LC3bI ratio in mice in the presence of the treatments indicated, compared 
with control mice (CTR). ANOVA (F = 6.26; df 3; p < 0.01) revealed a significant effect of the treatments on 
the LC3bII/LC3bI ratio. (e) Densitometric analyses of Western blot showing p62 expression in mice in the 
presence of the treatments indicated, compared with control mice (CTR). Values were normalized to Gapdh. 
ANOVA (F = 5.92; df 3; p < 0.008) revealed a significant effect of treatments on p62 protein expression. Data are 
presented as mean ± SEM. *p < 0.05; ** p < 0.005 by Tukey’s HSD test.
www.nature.com/scientificreports/
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underlying healing (short-term) and/or damaging (long-term) processes: exercise may induce muscle adapta-
tion to damage, but exposing severely cachectic tumor-bearing mice to exercise protocols might be deleterious. 
Consequently, pharmacological alternatives to physical activity should be considered.
Within this context, the results of our study show that one of the molecular pathways involved in cancer 
cachexia, i.e. autophagy, is directly responsible for the induction of skeletal muscle atrophy. It may thus be possible 
to use pharmacological treatments designed to trigger this cellular signal to improve muscle mass maintenance 
in cancer patients. We observed similar patterns of LC3bII and p62 protein levels in skeletal muscle biopsies 
from both colon carcinoma patients and C26-bearing mice, which were characterized by an accumulation of the 
lipidated form LC3b and the p62 protein. The fact that autophagocytosis normally degrades p62, whose levels 
thus become negligible, suggests that the autophagic flux is altered in the skeletal muscle of both animal models 
and human beings. In keeping with our findings, a recent study proved that autophagy is over-induced in skele-
tal muscle and contributes to muscle atrophy in cancer cachexia32. In that study, however, colchicine treatment, 
which blocks the autophagic flux after autophagosome formation49, anticipated the death of C26-bearing mice, 
thereby suggesting that a complete block in the autophagic flux is deleterious in cancer cachexia. The results of our 
study confirm the activation of the autophagic pathway, demonstrated by increased levels of the lipidated form of 
LC3b, and a delay in autophagosome clearance, demonstrated by the accumulation of p62, in the skeletal muscle 
of C26-bearing mice. Our in vitro observations with chloroquine also confirmed that a block in the autophagic 
flux is detrimental to skeletal muscle mass. The novelty of our findings stems from the fact that drugs promoting, 
and not inhibiting, the autophagic flux are effective against cancer cachexia. Despite being counter-intuitive, 
since autophagy may appear to be an additional catabolic pathway leading to sarcomere dismantling in cachexia, 
the model we propose suggests that it is of paramount importance to maintain balanced and efficient autophagy, 
which is dysregulated in cachexia, to improve muscle homeostasis. Autophagy is required at physiological levels 
for the removal of misfolded proteins and damaged organelles, and to prevent the accumulation of protein aggre-
gates50. Autophagy has also been reported to play a key role in skeletal muscle homeostasis27. Skeletal muscles 
Figure 5. Both AICAR and rapamycin treatments counteract C2C12 myotube atrophy induced by C26 
conditioned medium. (a) Representative immunostaining for myosin heavy chain on C2C12 myotubes 
cultured for 48 hours in the absence (CTR) or presence of C26-conditioned medium (C26), in the absence 
(—) or presence of 1 milliM AICAR, or 500 nanoM rapamycin, without (− CQ) or with (+ CQ) 50 microM 
chloroquine. Scale bar = 20 microns. (b) Quantification of C2C12 myotube diameters in all the aforementioned 
conditions. n = 5. $p < 0.0001vs -CQ; * * p < 0.001; * * * p < 0.0001.
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of autophagy-deficient mice progressively develop myopathy with age, and upon autophagy-triggering stresses, 
such as denervation or fasting, they severely degenerate owing to the accumulation of ubiquitinated proteins and 
damaged organelles51. Many studies have shown that an incorrect autophagic flux correlates with, and some-
times contributes to, skeletal muscle diseases such as Bethlem myopathy52, various muscular dystrophies53,54 and 
cancer cachexia32. The fact that treatment with two different drugs known to trigger autophagy, i.e. AICAR and 
rapamycin, improved muscle homeostasis in cancer cachexia strongly suggests that cachexia can be counteracted 
by triggering autophagy. AICAR has already been used to recover the autophagic flux in skeletal muscle and to 
counteract Duchenne muscular dystrophy in mice55. Rapamycin has instead been used as an immunosuppressant 
and anti-cancer drug46, though its effect on skeletal muscle wasting has never been investigated. Since AICAR 
and rapamycin, as well as other drugs that target AMPK such as metformin56, are currently being tested in can-
cer clinical trials57, these pharmacological treatments may be readily available for the translational applications 
deriving from our study. To prove that skeletal muscle cells are directly affected by AICAR, rapamycin and factors 
derived from C26 tumor cells, we reproduced cancer-derived muscle atrophy in vitro by treating myotubes with 
C26-conditioned media in the absence or presence of pharmacological treatments. Treatment with AICAR or 
rapamycin prevented C26-induced C2C12 myotube atrophy, thus proving that skeletal muscle cells are targeted 
by these drugs. Moreover, a block in the autophagic flux prevented the rescue of C26-induced myotube atrophy 
mediated by AICAR or rapamycin, thus indicating that both drugs regulate muscle homeostasis by promoting 
the autophagic flux.
In conclusion, the pharmacological treatments used in our study and exercise share the ability to counteract 
cachexia and restore autophagic levels to those found in control healthy muscles. In vitro studies show that mus-
cle cells are direct targets of both tumor-derived factors and exercise mimetics involved in the rescue of muscle 
mass homeostasis through a process involving the autophagic flux. A graphical abstract of our findings is shown 
in Fig. 6. To date, we cannot establish a causative role between the accumulation of autophagic markers and 
worsened cachexia, nor can we rule out the possibility that exercise and pharmacological treatments ameliorate 
C26-induced cachexia through indirect effects on muscle. In this regard, voluntary running was recently demon-
strated to directly counteract tumor growth in tumor-bearing mice by modulating the inflammation of the tumor 
microenvironment58 However, our study provides unequivocal evidence showing that physical activity or exercise 
Figure 6. Exercise, AICAR and rapamycin counteract muscle wasting in cancer cachexia and modulate an 
adequate autophagic flux level. (A) In physiological conditions, a balance between autophagosome production 
and clearance maintains an adequate autophagic flux (red arrow) in the muscles, mirrored by basal levels 
of LC3bII (black dots) and p62 (green dots) expression. In cachectic muscles from C26-bearing mice (B), a 
strong accumulation of both LC3bII and p62 proteins points to an unbalanced autophagosome production/
clearance ratio. This correlates with the pathophysiological features observed in cancer-related muscle wasting, 
including overexpression of Atrogin1 and Murf1 genes, as well as a decline in body weight (BD), muscle weight 
(MW), fiber size and muscle function. Spontaneous wheel running, or treatment with AICAR or rapamycin 
(C) counteracts cancer-related muscle wasting in tumor-bearing mice and induces a decrease in both LC3bII 
and p62 accumulation. Atrogin1 and Murf1 gene expression was restored to the basal levels observed in healthy 
muscles. This is associated with increased body and muscle weight and improved muscle function.
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mimetics help to preserve muscle mass in the presence of a tumor and should be taken into consideration when 
planning therapies to treat cancer cachexia.
Methods
Mice and patients. Cachexia was induced by subcutaneous grafting of a 0.5 mm3 fragment of colon carci-
noma (C26, obtained from the National Cancer Institute) in the dorsal region of 7-week-old BALB/c female mice 
(Charles River, Wilmington, MA), as previously described29. Unless otherwise specified, animals were sacrificed 
19 days following tumor transplantation, on the basis of our evidence from survival curves showing that the vast 
majority of animals are still alive at this time point, even in the presence of overt cachexia. Mice were treated 
strictly according to the guidelines of the Institutional Animal Care and Use Committee, and to relevant national 
and European legislation, throughout the experiments. All the experimental protocols were approved by the 
Organ for Prevention and Wellbeing of Animals (OPBA) of the University of Palermo and by the Charles Darwin 
ethics committee n°5 in Paris and sent to the respective Ministries of Research in the two countries. Informed 
consent was obtained from patients for muscle biopsies.
Exercise protocols and environmental enrichment. Wheels for rodents, with a diameter of 15 cm, 
were purchased in general customer pet shops. DC-9 tachometers were purchased from Decathlon. The mice 
were kept individually in cages that were identical, the only exception being that those of the WR mice were 
equipped with a wheel, as described in44, and were allowed to exercise ad libitum from the first day of the experi-
ment, i.e. from the day of transplantation in tumor-bearing mice so as to mimic clinical studies in which physical 
activity started at the time of diagnosis. Since wheel-running activity may represent an environmental enrich-
ment30, we set up additional, custom-made cages, characterized by the presence of novel objects, separate food 
reserves and tunnels, designed in such a way as to represent an environment enrichment59, to which a wheel was 
or was not added.
Drug administration. Mice were treated daily by means of an intraperitoneal (IP) injection of 250 mg/Kg 
AICAR water solution (9 mice) or of a vehicle (18 mice), or of 2 mg/kg rapamycin in physiologic solution contain-
ing 1% ethanol (12 mice), or of a physiologic solution containing 1% ethanol (8 mice, which were subsequently 
pooled with the other vehicle group since no statistically significant difference between these two groups was 
detected in any parameter throughout the study). Treatments with both AICAR and rapamycin started on the 
day after tumor transplantation and stopped at sacrifice. All the groups in a given experiment were sacrificed on 
the same day, which was selected depending on the extent of cachexia developed by C26-bearing, non-treated 
animals. The latter were considered cachectic when they had lost at least 10% of their body weight.
Histological and immunofluorescence analyses. TA muscles were dissected, embedded in 
tissue-freezing medium (Leica, Wetzlar, Germany) and frozen in liquid nitrogen-cooled isopentane. Cryosections 
(8 μ m) were obtained using a Leica cryostat. Transverse cryosections of TA muscles were fixed in 4% paraformal-
dehyde for 10 min at room temperature. For p62 immunofluorescence analyses, muscles were permeabilized with 
0.2% Triton in PBS for 30 min. After incubation with 1% BSA (Sigma, St. Lous, MO) for 30 min, samples were 
incubated with a 1:100 dilution in 1% BSA of polyclonal rabbit anti-laminin antibody (Sigma) or a 1:50 dilution 
in 1% BSA of anti-p62 guinea pig antibody (Progen) overnight at 4 degrees, followed by incubation with a 1:500 
dilution in BSA of anti-rabbit-Alexa 488 or anti-guinea pig-Alexa 488 (Life Technologies) secondary antibodies 
for 1 hour at room temperature. 0.5 ug/ml Hoechst 33342 (Sigma) was used to stain nuclei.
Morphometric analyses. Cross-sectional areas of TA myofibers were measured by using ImageJ soft-
ware, freely availabe at http://imagej.nih.gov/ij/docs/intro.html. The whole muscle cross-sections from seven 
AICAR-treated mice or from seven vehicle-treated mice, and from five rapamycin-treated mice or from seven 
vehicle-treated mice were analyzed.
Myotube atrophy was quantified by measuring myotube diameter using ImageJ software. For each replicate 
sample, ten photomicrographs, each containing approximately 100 myotubes, were analyzed and the median 
myotube diameter (measured at the level of the maximum diameter displayed by each myotube) was calculated.
Functional analyses. Fatigue time was measured as previously described. Briefly, the EDL muscle was 
mounted vertically in an ASI 300 b Dual-Mode actuator/transducer. To induce isometric fatigue, muscles were 
subjected to a series of closer trains of pulses (0.4 s train of 120 Hertz pulses) and the time required to halve the 
value of their own maximum strength was calculated.
RNA extraction and Real-time PCR analyses. Total RNA was isolated and purified from 30–50 mg of 
TA muscle using Trizol Reagent (Invitrogen), according to the manufacturer’s protocol. One microgram of total 
RNA was converted to cDNA using the QuantiTect Reverse Transcription Kit (Qiagen). Real-time PCR was per-
formed with the SDS-ABI Prism 7500 (Applied Biosystem, Life Technologies, Monza, IT), using the Sybr Green 
reaction mix (Applied Biosystem).
The following primer sequences were used:
atrogin1 for: GCA AAC ACT GCC ACA TTC TCT C
atrogin1 rev: CTT GAG GGG AAA GTG AGA CG
MuRF-1 for: ACC TGC TGG TGG AAA ACA TC
MuRF-1 rev: CTT CGT GTT CCT TGC ACA TC
myostatin for : TGC TGT AAC CTT CCC AGG ACC A
myostatin rev: GTG AGG GGG TAG CGA CAG CAC
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GAPDH for ACC CAG AAG ACT GTG GAT GG
GAPDH rev CAC ATT GGG GGT AGG AAC AC
Five control healthy mice, six C26-bearing mice, six C26 WR, six vehicles, and five mice treated with either 
AICAR or rapamycin were analyzed.
Western blot analyses. TA muscles were dissected, minced and homogenized in 0.4 ml of lysis buffer 
(50 mM Tris-HCl pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% TRITON) supplemented with protease and phosphate 
inhibitors (complete Mini EDTA free and PhosSTOP, Roche). Cryosections from frozen rectus abdominis muscle 
biopsies of colon carcinoma patients were lysed in the same buffer as described above and used for further analy-
ses. Proteins (30–50 micrograms) were separated by means of SDS-PAGE with varying % of acrylamide, depend-
ing on the protein molecular weight to be analyzed, and transferred to PVDF membrane (Invitrogen). Unspecific 
bindings were blocked in 5% non-fat dry milk (Nestlé) in TBST 1× (20 mM Tris, 137 mM NaCl, 0.1% Tween 20) 
for 1 hour at room temperature; membranes were then incubated at 4 °C, overnight, with primary antibody 
diluted in 5% BSA (Sigma) in TBST. The following primary antibody and dilutions were used: P-mTOR S2448 
(Cell Signalling) 1:100; mTOR (Cell Signalling) 1:100; P-AMPKalpha T172 (Cell Signalling) 1: 1000; AMPKalpha 
(Cell Signalling) 1:1000; p-Acetyl-CoA Carbossylase S79 (Cell Signalling) 1:100; LC3b (Cell Signalling) 1:1000; 
p62 (Sigma) 1:10000; GAPDH (Santa Cruz) 1:10000; tubulin (Sigma) 1:10000. After washing in TBST, mem-
branes were incubated for 1 hour at room temperature with HRP-conjugated anti-mouse or anti-rabbit secondary 
antibodies (Biorad) diluted 1:10000 in TBST, and signals were detected using ECL reagent (Advasta). Intensity of 
Western blot signals was quantified by using ImageJ software. Five control healthy mice, four C26 (—), four C26 
WR, four AICAR-treated and four rapamycin-treated mice were analyzed.
Statistical analyses. For each set of data, the first step entailed verifying the normal distribution of the data 
and their homoscedasticity by means of Levene’s test. If the data were homoscedastic, one- or two-way analysis of 
variance (ANOVA) was used, followed by Tukey’s HSD as a post-hoc test. If data were not homoscedastic (and in 
case of an unsuccessful transformation attempt), the data were analyzed using non-parametric tests, such as the 
Kruskal-Wallis test. Student’s t-test was used when only two treatments were compared. A Cox model was used 
to treat and analyze the survival curves. The specific test used and the global effects are indicated in the Results, 
while the specific post-hoc test used and the significance level of specific comparisons are indicated in the Figure 
legends, which also indicate the number of samples analyzed. All values are expressed as mean ± standard error 
of the mean (SEM) or as median ± semi-interquartile range, as appropriate.Both ISSP and VassarStats, a statistical 
computation website that is available for free at http://vassarstats.net/, were used as softwares for the statistical 
analysis.
In vitro experiments. C26-conditioned medium was obtained by culturing confluent C26 cells (CLS Cell 
Lines Service GmbH, Eppelheim, Germany) for 2 days in serum-free DMEM (this C26 cell-conditioned medium 
was diluted 1 to 5 (20% final concentration) to treat C2C12 cultures (DMEM stored for 2 days at 37 °C used for 
controls). C2C12 cells were seeded at 20000 cells/cm2 and cultured in growing conditions (GM, DMEM con-
taining 1% glutamine, 2% HEPES, 0.5% gentamicin, supplemented with 10% FBS, SIgma); the following day 
the cells were shifted to DMEM supplemented with 2% horse serum (DM, Sigma) and induced to differentiate 
for 4 days. C2C12 myotubes were cultured for 2 additional days with DM, in the absence or presence of 20% of 
C26-conditioned medium, with or without 1 mM AICAR (Sellckchem) or 50 nM rapamycin (Sellckchem) in 
0.0025 DMSO solution. To block the autophagic flux, 50microM cloroquine (SIGMA) was added for 6 hours at 
the beginning of the treatments described above to 4-day myotube cultures; the samples were then extensively 
washed and incubated with the corresponding treatment for the remaining time until the end of the experiment.
Immunofluorescence analyses. Cells were fixed in 4% PFA for 10 min at RT, permeabilized with 1% BSA 
plus 0.2% Triton in phosphate-buffered saline (PBS) and blocked in 5% goat serum (SIGMA) in PBS for 1 hour. 
Cells were incubated with a 1:50 dilution of p62 (Progen), or 1:50 dilution of LC3b (Cell Signaling), or 1:10 dilu-
tion of MF20 (Hybridoma Bank) in 1% BSA in PBS overnight at 4 degrees. Primary antibody incubation was 
followed by incubation with a 1:500 dilution in 1% BSA of secondary antibody anti-guinea pig, anti-rabbit or 
anti-mouse Alexa (Life technologies) for 1 hour at room temperature. 0.5 μ g/mL Hoechst 33342 (SIGMA) was 
used to stain nuclei.
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